In anaplastic thyroid carcinoma (ATC) in humans, PPARγ agonists can inhibit the secretion of CCL2 in some tumor cells and simultaneously suppress the activation of NF-κB and ERK1/2 signaling pathways (157). The gene discussed is CCL2; the disease is neoplasm.